New insurance plan covers pioneering treatments abroad

MediVISA insurance offers treatment not available on the NHS or in the UK, at international medical facilities with pioneering therapies.

Virtual insurer SecurityTrust has launched MediVISA a medical insurance plan covering cancer, heart diseases, neurological conditions and other illnesses. Cover includes stem cell treatment, proton therapy, bone marrow and organ transplants.

The policy offers treatment not available on the NHS or in the UK, at international medical facilities with pioneering therapies.

MediVISA offers customers and their dependents access to the latest and most advanced treatments, therapies and procedures available, including stem cell treatment, proton therapy, bone marrow and organ transplantation.

The plan offers two versions – Standard and Gold – which provide two different levels of cover for the following benefits: UK treatment, hospitalisation and care; lump sum benefit post-treatment abroad; second medical opinion; travel costs; accommodation costs; daily cash allowance; medication; repatriation of mortal remains; and optional UK cover.

Unless the customer opts for UK cover, after diagnosis, all treatment will be in a hospital outside the UK.

Once a diagnosis has been confirmed, a claims and concierge service provides a second opinion service; lump sum and daily cash benefits; travel and accommodation expenses for both the insured person and a companion, and all arrangements are directly booked, organised and paid for.

MediVISA is administered by Dual Corporate Risks, underwritten at Lloyd’s of London, and sold by insurance brokers in the UK.

David Abingdon at SecurityTrust says: “MediVISA is a ground-breaking plan that makes healthcare for serious illnesses affordable for most people and their families. Policyholders have the choice to accept treatment abroad or at home.”

MediVISA is available with immediate cover on a blanket moratorium on any covered condition suffered in the last 10 years being excluded.

Cover is available only for UK residents on an individual or company employee group basis.

None of the information or documentation reveals which hospitals or even which countries or hospitals the customer gets treatment in, other than vague suggestions that they will be given a choice.